实施例1
合成路线1
在干燥的250mL圆底烧瓶中加入1(10.00g,51.0mmol),p-TSA(1.75g,10.2mmol)和二氯甲烷(100.0mL),缓慢滴加DHP(8.56g,102.0mmol),室温下搅拌4.0h。反应完毕后,反应液用100.0mL水稀释,200mL二氯甲烷萃取2次,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物2(8.90g,62%)。LCMS:281(M+H)+,RT=1.626mim。
在干燥的250mL圆底烧瓶中室温下依次加入化合物2(8.90g,31.7mmol),3(5.77g,31.7mmol),Pd(PPh3)4(3.66g,3.17mmol),K2CO3(8.75g,63.4mmol),1,4-二氧六环(60.0mL)和水(15.0mL),搅拌至均匀分散于体系中。在氮气保护下,加热回流4.0h。反应液冷却至室温,旋干溶剂得粗产品,柱层析(乙酸乙酯:石油醚=1:10)得化合物4(8.10g,76%)。LCMS:339(M+H)+,RT=1.626mim.
在干燥的250mL圆底烧瓶中加入化合物4(7.90g,23.4mmol)和二氯甲烷(50.0mL),缓慢滴加SO2Cl2(7.15g,46.7mmol),室温下搅拌4.0h。反应液加入50.0mL水稀释,200mL二氯甲烷萃取2次,饱和NaHCO3溶液洗剂,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物5(8.50g,89%)。LCMS:407(M+H)+,RT=1.798mim.
在干燥的250mL圆底烧瓶中加入化合物5(8.50g,20.9mmol)和盐酸甲醇溶液(1M)(80.0mL),加热回流16.0h。反应液旋干溶剂得7.50g的化合物6,无需纯化直接用于下一步。LCMS:323(M+H)+,RT=1.592mim。
在干燥的250mL圆底烧瓶中加入化合物6(7.40g,23.0mmol),碘(11.68g,46.0mmol),NaOH(1.84g,46.0mmol)和1,4-二氧六环(60.0mL)。室温下搅拌2.0h。反应完毕后,加入200mL水,混合物用200mL二氯甲烷萃取2次,有机相用饱和硫代硫酸钠溶液洗涤,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物7(9.50g,92%)。LCMS:449(M+H)+,RT=1.644mim.
在干燥的250mL圆底烧瓶中加入7(9.30g,20.76mmol),p-TSA(0.71g,4.152mmol)和二氯甲烷(50.0mL),缓慢滴加DHP(3.48g,41.52mmol),室温下搅拌4.0h。反应液用50.0mL水稀释,200mL二氯甲烷萃取2次,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物8(7.70g,70%)。LCMS:281(M+H)+,RT=2.165mim.
1HNMR(CDCl3,400MHz)δ(ppm)7.56(d,1H,J=8.0Hz),7.45(s,1H),7.09(d,1H,J=8.0Hz),6.65(s,1H),5.70(t,1H,J=4.0Hz),4.03(s,1H),3.98(s,6H),3.69(t,1H,J=8.0Hz),2.53(t,1H,J=10Hz),2.12(m,2H),1.68-1.74(m,2H),1.56-1.63(m,1H).
将化合物9(10g,82.6mmol)置于500mL单口瓶中,加入200mLDMSO。室温下加入(2R,6S)-2,6-dimethylpiperazine(14g,124mmol)和K2CO3(28.5g,206.5mmol),搅拌均匀。然后加热到130℃,反应8h。反应完毕后,倒入1L水中。用乙酸乙酯(150mL*3)萃取三次。有机相用100mL饱和食盐水洗涤,无水硫酸钠干燥,旋干溶剂,得微黄色固体15g,产率85%。
1HNMR(400MHz,CDCl3)δ(ppm)7.48(2H,d,J=8.8Hz),6.85(2H,d,J=8.0Hz),3.65(2H,dd,J1=12.0Hz,J2=2.0Hz),2.95-3.01(2H,m),2.42(2H,t,J=11.4Hz),1.15(6H,d,J=6.4Hz).
把化合物11(9.03g,42mmol)溶解于175mL乙醇中,然后室温下向溶液中依次加入NaOH(6.0N,105ml)和H2O2(16.1ml)。升温至50摄氏度,搅拌5个小时。反应完毕后,冷却至0摄氏度,用3N的硫酸调至PH值为7.旋蒸掉有机相,0度下搅拌30分钟。过滤得到白色固体6.5g,产率为66%。
1HNMR(400MHz,DMSO-d6):δ(ppm)7.76(2H,d,J=8.8Hz),7.73(1H,br),7.04(1H,br),6.97(2H,d,J=8.8Hz),3.85(2H,d,J=11.2Hz),3.08(2H,br),2.45(2H,t,J=11.6Hz),1.15(6H,d,J=6.4Hz).
把化合物8(2.0g,3.75mmol)溶解于20mL无水DMF中,然后室温下向溶液中依次加入反式-N,N’-二甲基-1,2-环己二胺(107mg,0.75mmol)、CuI(36mg,0.19mmol)、K3PO4(1.6g,7.5mmol)和12(1.05g,4.5mmol)。氮气置换3次,升温至110摄氏度,搅拌16个小时。反应完毕后,旋蒸掉溶剂得粗产品,柱层析(二氯甲烷:甲醇=40:1)得白色固体0.98g,产率为41%。
1HNMR(CDCl3,400MHz)δ(ppm)8.46(s,1H),8.22(d,1H,J=8.0Hz),7.86(d,2H,J=8.0Hz),7.35(s,1H),7.01(d,1H,J=8.0Hz),6.94(d,2H,J=8.0Hz),6.62(s,1H),,5.61(m,1H),3.96(s,6H),3.71(m,3H),3.06(m,2H),2.48(m,3H),2.06(m,3H),1.70(m,3H),1.20(s,3H),1.18(s,3H).
把化合物13(0.86g,1.35mmol)溶解于10mL二氯甲烷中,然后室温下向溶液中加入三氟乙酸(5ml)。室温下搅拌4个小时。反应完毕后,旋蒸掉溶剂得粗产品,柱层析(二氯甲烷:甲醇=20:1)得白色固体0.61g,产率为82%。
1HNMR(CDCl3,400MHz)δ(ppm)8.79(s,1H),8.15(d,1H,J=8.0Hz),7.86(d,2H,J=8.0Hz),7.26(s,1H),6.99(d,1H,J=8.0Hz),6.89(d,2H,J=8.0Hz),6.62(s,1H),3.96(s,6H),3.65(m,2H),3.06(m,2H),1.17(s,3H),1.15(s,3H).
使用类似方法可得到如下化合物:
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-甲基哌嗪-1-基)苯甲酰胺
1HNMR(CDCl3,400MHz)δ(ppm)8.83(s,1H),8.21(d,1H,J=8.0Hz),7.89(d,2H,J=8.0Hz),7.23(s,1H),6.99(d,1H,J=8.0Hz),6.91(d,2H,J=8.0Hz),6.61(s,1H),3.95(s,6H),3.33(m,4H),2.56(m,4H),2.35(s,3H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-((4-甲基哌嗪-1-基)甲基)苯甲酰胺
1HNMR(MeOD,400MHz)δ(ppm)8.03(d,2H,J=8.0Hz),7.84(d,1H,J=8.0Hz),7.53(d,2H,J=8.0Hz),7.29(s,1H),6.93(d,1H,J=8.0Hz),6.87(s,1H),3.97(s,6H),3.68(s,2H),2.98(br,4H),2.56(br,4H),2.54(s,3H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-***啉苯酰胺
1HNMR(MeOD,400MHz)δ(ppm)8.02(d,2H,J=8.0Hz),7.97(d,1H,J=8.0Hz),7.32(s,1H),7.07(d,2H,J=8.0Hz),7.99(d,1H,J=8.0Hz),6.88(s,1H),3.98(s,6H),3.84(t,4H,J=5.2Hz),3.33(t,4H,J=5.2Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-乙基哌嗪-1-基)苯甲酰胺
1HNMR(MeOD,400MHz)δ(ppm)8.09(m,3H),7.36(s,1H),7.20(m,2H),7.99(m,1H),6.89(s,1H),3.97(s,6H),3.27(m,2H),1.4(t,3H,J=6.4Hz).
4-((4-乙酰基-1-基)甲基)-N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)苯甲酰胺
1HNMR(DMSO-d6,400MHz)δ(ppm)12.88(s,1H),10.81(s,1H),8.06(d,2H,J=8.0Hz),7.77(d,1H,J=8.0Hz),7.78(d,2H,J=8.0Hz),7.29(s,1H),7.00(s,1H),6.85(d,1H,J=8.0Hz),3.97(s,6H),3.59(s,2H),2.40(t,2H,J=4.8Hz),2.33(t,2H,J=4.8Hz),1.98(s,3H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-((2-(二甲基氨基)乙基)氨基)苯甲酰胺
1HNMR(400MHz,DMSO-d6/D2O)δ(ppm)7.87(2H,s),7.71(1H,s),7.29(1H,s),7.10-6.60(4H,m),3.91(6H,s),3.70(2H,s),3.48(2H,s),2.80(6H,s).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-5-((3R,5S)-3,5-二甲基-1-基)吡啶酰胺
1HNMR(DMSO-d6,400MHz)δ(ppm)12.89(1H,br),10.48(1H,s),9.06(1H,br),8.51(2H,br),8.05(1H,d,J=8.8Hz),7.94(1H,d,J=8.4Hz),7.60-7.63(1H,m),7.29(1H,s),7.01(1H,s),4.22(2H,d,J=14.4Hz),3.97(6H,s),2.84(2H,t,J=12.6Hz),2.54-2.58(2H,m),1.30(6H,d,J=6.4Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(3,3-二甲基-1-基)苯甲酰胺
1HNMR(400MHz,DMSO-d6)δ(ppm)12.85(s,1H),10.57(s,1H),8.01(2H,d,J=8.8Hz),7.76(1H,d,J=8.4Hz),7.29(s,1H),7.07(2H,d,J=8.8Hz),7.01(1H,s),6.85(d,1H,J=8.4Hz),3.98(s,6H),3.18-3.50(m,6H),1.31(s,6H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-3-(4-甲基-1-基)苯甲酰胺
1HNMR(400MHz,DMSO-d6)δ(ppm)12.92(1H,s),10.83(1H,s),9.60-9.20(1H,m),7.78(1H,d,J=8.4Hz),7.68(1H,s),7.58(1H,d,J=7.6Hz),7.44(1H,t,J=8.0Hz),7.30(1H,s),7.26(1H,dd,J1=1.6Hz,J2=8.0Hz),7.00(1H,s),6.87(1H,d,J=8.4Hz),3.97(6H,s),3.30-3.10(4H,m),3.10-2.80(4H,m),2.88(3H,s).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-异丙-1-基)苯甲酰胺
1HNMR(MeOD,400MHz)δ(ppm)8.08(br,2H),7.99(br,1H),7.33(br,1H),7.18(br,2H),7.02(br,1H),6.89(s,1H),4.11-4.17(m,2H),3.57-3.64(m,3H),3.19-3.37(m,4H),1.42(6H,d,J=6.4Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(哌嗪-1-基)苯甲酰胺
1HNMR(MeOD,400MHz)δ(ppm)8.00(2H,d,J=9.2Hz),7.83(1H,d,J=8.4Hz),7.28(s,1H),7.10(2H,d,J=9.2Hz),6.90(1H,d,J=8.4Hz),6.88(s,1H),3.97(s,6H),3.48-3.51(m,4H),3.18-3.25(m,4H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-((3(二甲基氨基)丙基)氨基)苯甲酰胺
1HNMR(400MHz,DMSO-d6)δ(ppm)12.87(1H,br),10.39(s,1H),9.57(1H,br),7.80(2H,d,J=8.8Hz),7.75(1H,d,J=8.4Hz),7.27(s,1H),6.84(1H,d,J=8.4Hz),6.66(2H,d,J-8.8Hz),3.98(6H,s),3.20(4H,t,J=6.8Hz),2.80(s,6H),1.89-1.96(m,2H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-(2-羟乙基)哌嗪基)苯甲酰胺
1HNMR(400MHz,DMSO-d6)δ(ppm)12.85(1H,br),10.62(1H,s),9.73(1H,br),8.05(2H,d,J=8.8Hz),7.76(1H,d,J=8.4Hz),7.29(1H,s),7.13(2H,d,J=8.8Hz),6.87(1H,s),6.86(1H,d,J=8.4Hz),4.06-4.08(m,2H),3.98(6H,s),3.80(2H,t,J=4.8Hz),3.56-3.60(m,2H),3.14-3.28(m,6H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(2-(二甲基氨基)乙酰氨基)苯甲酰胺
1HNMR(400MHz,DMSO-d6)δ(ppm)12.92(1H,s),10.78(1H,s),10.08(1H,s),8.12(2H,d,J=8.8Hz),7.89(2H,d,J=8.8Hz),7.83(1H,d,J=8.4Hz),7.34(1H,s),7.06(1H,s),6.91(1H,d,J=8.4Hz),4.03(6H,s),3.18(s,2H),2.35(s,6H).
N-(6-(3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-((3R,5S)-3,5-二甲基哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.78(s,1H),10.50(s,1H),7.97(d,2H,J=9.2Hz),7.76(d,1H,J=8.4Hz),7.66(s,1H),7.36(d,1H,J=8.4Hz),7.01(d,2H,J=8.8Hz),6.84(d,2H,J=2.0Hz),6.53(s,1H),3.83(s,6H),3.76(d,2H,J=6.8Hz),2.83(s,2H),2.24(t,3H,J=6.8Hz),1.23(s,4H),1.04(d,6H,J=6.4Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-特戊酰基哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.81(s,1H),10.6(s,1H),8.01(d,2H,J=8.8Hz),7.75(d,1H,J=4.4Hz),7.27(s,1H),7.03(d,2H,J=8.8Hz),7.00(s,1H),6.84(d,1H,j=8.8Hz),4.00(s,6H),3.70-3.72(m,4H),3.30-3.32(m,4H),1.23(s,9H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-1-(2-羟基乙基)-1H-吡唑-4-甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.84(brs,1H),10.53(s,1H),8.41(s,1H),8.11(s,1H),7.80(d,1H,J=8.4Hz),7.26(s,1H),7.01(d,1H,J=3.2Hz),6.84(d,1H,J=8.4Hz),4.21(t,2H,J=5.2Hz),3.94(s,6H),3.77(t,2H,J=5.2Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-2,3-二氢咪唑并[5,1-B]噁唑-7-甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.80(brs,1H),10.18(s,1H),8.07(s,1H),7.77(d,1H,J=8.0Hz),7.25(s,1H),7.00(s,1H),6.83(dd,1H,J1=0.8Hz,J2=8.4Hz),5.23(t,2H,J=7.6Hz),4.33(t,2H,J=8.0Hz),3.97(s,6H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(3-(二甲基氨基)-3-氧代丙基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.90(s,1H),10.78(s,1H),8.00(d,2H,J=8.4Hz),7.77(d,1H,J=8.4Hz),7.42(d,2H,J=8.0Hz),7.03(s,1H),7.01(d,1H),6.86(d,1H,J=8.4Hz),3.98(s,6H),2.91(t,2H,J=14.4Hz),2.84(s,3H),2.67(t,2H,J=14.4Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-((二甲基氨基)甲基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.95(s,1H),10.97(s,1H),9.85(d,1H,J=2.8Hz),8.17(d,2H,J=8.0Hz),7.78(d,1H,J=8.0Hz),7.66(d,2H,J=8.4Hz),7.31(s,1H),7.00(s,1H),6.87(d,1H,J=8.4Hz),4.39(d,2H,J=4.4Hz),3.97(s,6H),2.79(t,6H,J=3.6Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(二甲基氨基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.82(s,1H),10.47(s,1H),7.98(d,2H,J=6.4Hz),7.76(d,1H,J=8.0Hz),7.28(s,1H),7.03(s,1H),7.01(s,1H),6.84(d,1H,J=8.4Hz),6.78(d,2H,J=6.8Hz),3.98(s,6H),3.18(s,6H).
4-(4-乙酰基哌嗪-1-基)-N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑-3-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.89(s,1H),10.62(s,1H),8.06(d,2H,J=8.8Hz),7.82(d,1H,J=8.4Hz),7.34(s,1H),7.10(d,2H,J=8.8Hz),7.06(s,1H),6.84(d,1H,j=8.4Hz),4.03(s,6H),3.65-3.66(m,4H),3.38-3.43(m,4H),2.10(s,3H).
N-(6-(2,6-二氯-3,5-二甲氧苯基)-1H-吲唑-3-基)-4-(4-(二甲基氨基)哌啶-1-基)苯甲酰胺
1HNMR(CDCl3,400MHz)δppm8.48(s,1H),8.23(d,1H,J=8Hz),7.88(d,2H,J=8.8Hz),7.02(d,1H,J=8.8Hz),6.79(d,2H,J=8.4Hz),6.63(s,1H),3.97(s,6H),3.93(d,2H,J=14Hz),2.84-2.87(m,2H),2.33(m,7H),1.95(d,4H,J=12Hz)。LCMS:568(M+H)+,RT=1.25min
合成路线2
在干燥的50mL圆底烧瓶中加入化合物38(1.20g,3.55mmol)和乙腈(20.0mL)。N2保护0℃下分批加入SelectFlour(2.51g,7.1mmol),室温搅拌18.0h。反应液用水稀释,乙酸乙酯萃取,有机相依次用水,饱和NaHCO3,饱和食盐水洗涤。无水硫酸钠干燥,旋干溶剂得粗产品,柱层析(乙酸乙酯:石油醚=1:8)得粗产物化合物39(629mg,47%)。LCMS:374.9(M+H)+,RT=1.243min.
在干燥的50mL圆底烧瓶中加入化合物39(629mg,1.68mmol)和二氯甲烷(10.0mL),冰浴下缓慢滴加TFA(2mL),室温下搅拌3.0h。旋干溶剂,剩余物用冰水稀释,饱和NaHCO3溶液调节pH=8,乙酸乙酯萃取,有机相用水洗。无水硫酸钠干燥,旋干溶剂得粗产物化合物40(460mg,94%)。LCMS:291.0(M+H)+,RT=1.233min.
在干燥的50mL圆底烧瓶中加入化合物40(460mg,1.59mmol),水溶液NaOH(5.3mL,3N)和1,4-二氧六环(6.0mL)。零度下滴加碘(484.0mg,1.90mmol)的1,4-二氧六环溶液。室温搅拌18.0h。饱和硫代硫酸钠溶液洗剂,乙酸乙酯萃取,有机相依次用水和饱和食盐水洗涤,无水硫酸钠干燥,旋干得粗产物41(633.0mg,95.6%)无需纯化直接用于下一步。LCMS:416.9(M+H)+,RT=1.540min。
在干燥的50mL圆底烧瓶中加入41(633.0mg,1.52mmol),p-TSA(58.0mg,0.30mmol)和二氯甲烷(6.0mL),缓慢滴加DHP(256.0mg,3.04mmol),室温下搅拌18.0h。反应液用20.0mL水稀释,二氯甲烷萃取,合并有机相,无水硫酸钠干燥,旋干溶剂得粗产品,柱层析(乙酸乙酯:石油醚=1:12)得化合物42(260.0mg,34%)。
在干燥的25mL三口烧瓶中加入42(260mg,0.52mmol),5a(145mg,0.62mmol),5b(148.0mg,1.04mmol),K3PO4(331.0mg,1.56mmol),CuI(99mg,0.52mmol),和干燥的DMF(3.0mL),120℃下搅拌6.0h。反应液用20.0mL水稀释,乙酸乙酯萃取,合并有机相,依次用水和饱和食盐水洗,无水硫酸钠干燥,旋干溶剂得粗产物化合物43(290mg,92%)无需纯化直接用于下一步。LCMS:606.1(M+H)+,RT=1.063min.
在干燥的25mL圆底烧瓶中加入43(290.0mg,0.48mmol)和二氯甲烷(10.0mL),冰水浴缓慢滴加TFA(2.0mL),室温下搅拌4.0h。旋干溶剂得粗产物,酸性prep-HPLC制备得化合物44(50.2mg,21%,TFA盐)。LCMS:522.1(M+H)+,RT=1.227min.
1HNMR(d6-DMSO,400MHz)δppm12.91(brs,1H),10.64(d,1H,J=3.2Hz),9.01(m,1H),8.45(m,1H),8.04(d,2H,J=8.8Hz),7.78(d,1H,J=8.4Hz),7.52(s,1H),7.09(m,4H),4.12(d,2H,J=13.8Hz),3.92(s,6H),2.77(m,3H),1.29(d,6H,J=6.4Hz).
使用类似方法可得到如下化合物:
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-甲基哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.95(s,1H),10.62(s,1H),9.78(s,1H),8.04(d,2H,J=8.8Hz),7.79(d,1H,J=8.4Hz),7.52(s,1H),7.02-7.18(m,4H),4.08(d,2H,J=12.0Hz),3.92(s,6H),3.47-3.63(m,2H),3.01-3.27(m,4H),2.88(s,3H).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(3,3-二甲基哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.91(s,1H),10.63(s,1H),8.91(s,2H),8.03(d,2H,J=9.2Hz),7.78(d,1H,J=8.0Hz),7.52(s,1H),7.02-7.16(m,4H),3.86(s,6H),3.51(m,2H),3.43(m,2H),3.30(s,2H),1.26(t,3H,J=7.2Hz).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-乙基哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm12.95(s,1H),10.62(s,1H),9.78(s,1H),8.04(d,2H,J=8.8Hz),7.79(d,1H,J=8.4Hz),7.52(s,1H),7.02-7.18(m,4H),4.08(d,2H,J=12.0Hz),3.92(s,6H),3.47-3.63(m,2H),3.21-3.22(m,2H),3.01-3.27(m,4H),1.27(t,3H,J=7.2Hz).
N-(6-(2,6-二氟-3,5-二甲氧苯基)-1H-吡唑[3,4-b]并吡啶-3-基)-4-(4-甲基哌嗪-1-基)苯甲酰胺
1HNMR(d-MeOD,400MHz)δppm8.50(d,1H,J=8.4Hz)),7.99(d,2H,J=8.8Hz),7.30(d,1H,J=8.4Hz),7.08(d,2H,J=8.8Hz),7.01(s,1H),3.93(s,6H),3.45(s,4H),2.80(s,4H),2.49(s,3H).LCMS:509(M+H)+,RT=1.18min
合成路线3
在干燥的50mL圆底烧瓶中加入化合物49(1.20g,3.55mmol)和乙腈(20.0mL)。N2保护0℃下分批加入SelectFlour(2.51g,7.1mmol),室温搅拌18.0h。反应液用水稀释,乙酸乙酯萃取,有机相依次用水,饱和NaHCO3,饱和食盐水洗涤。无水硫酸钠干燥,旋干溶剂得粗产品,柱层析(乙酸乙酯:石油醚=1:8)得粗产物化合物50(629mg,47%)。LCMS:374.9(M+H)+,RT=1.243min
在干燥的50mL圆底烧瓶中加入化合物50(629mg,1.68mmol)和二氯甲烷(10.0mL),冰浴下缓慢滴加TFA(2mL),室温下搅拌3.0h。旋干溶剂,剩余物用冰水稀释,饱和NaHCO3溶液调节pH=8,乙酸乙酯萃取,有机相用水洗。无水硫酸钠干燥,旋干溶剂得粗产物化合物51(460mg,95%)。LCMS:291.0(M+H)+,RT=1.233min.
在干燥的50mL圆底烧瓶中加入化合物51(460mg,1.59mmol),水溶液NaOH(5.3mL,3N)和1,4-二氧六环(6.0mL)。零度下滴加碘(484.0mg,1.90mmol)的1,4-二氧六环溶液。室温搅拌18.0h。饱和硫代硫酸钠溶液洗剂,乙酸乙酯萃取,有机相依次用水和饱和食盐水洗涤,无水硫酸钠干燥,旋干得粗产物52(633.0mg,96%)无需纯化直接用于下一步。LCMS:416.9(M+H)+,RT=1.540min。
在干燥的50mL圆底烧瓶中加入52(633.0mg,1.52mmol),p-TSA(58.0mg,0.30mmol)和二氯甲烷(6.0mL),缓慢滴加DHP(256.0mg,3.04mmol),室温下搅拌18.0h。反应液用20.0mL水稀释,二氯甲烷萃取,合并有机相,无水硫酸钠干燥,旋干溶剂得粗产品,柱层析(乙酸乙酯:石油醚=1:12)得化合物53(265.0mg,26%)。
在干燥的25mL三口烧瓶中加入53(193mg,0.40mmol),5a(112mg,0.48mmol),5b(114.0mg,0.81mmol),K3PO4(256.0mg,1.21mmol),CuI(76mg,0.40mmol),和干燥的DMF(3.0mL),120℃下搅拌6.0h。反应液用30.0mL水稀释,乙酸乙酯萃取,合并有机相,依次用水和饱和食盐水洗,无水硫酸钠干燥,旋干溶剂得粗产物化合物54(240mg,99%),无需纯化直接用于下一步。LCMS:588.1(M+H)+,RT=1.320min.
在干燥的25mL圆底烧瓶中加入54(240.0mg,0.41mmol)和二氯甲烷(7.5mL),冰水浴缓慢滴加TFA(1.5mL),室温下搅拌4.0h。旋干溶剂得粗产物,酸性prep-HPLC制备得化合物55(70.8mg,34%,TFAsalt)。LCMS:522.1(M+H)+,RT=1.227min.
1HNMR(d6-DMSO,400MHz)δppm12.95(brs,1H),10.61(s,1H),9.17(m,1H),8.57(m,1H),8.03(d,2H,J=9.2Hz),7.76(m,1H),7.59(s,1H),7.22(d,1H,J=8.8Hz),7.13(d,2H,J=9.2Hz),6.76(dd,1H,J1=2.8Hz,J2=6.8Hz),6.61(m,1H),4.01(d,2H,J=12.4Hz),3.88(s,1H),3.84(s,3H),3.81(s,3H),3.30-3.50(m,2H),2.75(t,2H,J=6.4Hz),1.29(d,6H,J=6.4Hz).
合成路线4
在干燥的250mL圆底烧瓶中加入56(10.00g,51.0mmol),p-TSA(1.75g,10.2mmol)和二氯甲烷(100.0mL),缓慢滴加DHP(8.56g,102.0mmol),室温下搅拌4.0h。反应完毕后,反应液用100.0mL水稀释,200mL二氯甲烷萃取2次,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物57(8.90g,62%)。LCMS:281(M+H)+,RT=1.626min。
在干燥的250mL圆底烧瓶中室温下依次加入化合物57(8.90g,31.7mmol),3(5.77g,31.7mmol),Pd(PPh3)4(3.66g,3.17mmol),K2CO3(8.75g,63.4mmol),1,4-二氧六环(60.0mL)和水(15.0mL),搅拌至均匀分散于体系中。在氮气保护下,加热回流4.0h。反应液冷却至室温,旋干溶剂得粗产品,柱层析(乙酸乙酯:石油醚=1:10)得化合物58(8.10g,76%)。LCMS:339(M+H)+,RT=1.626min.
在干燥的250mL圆底烧瓶中加入化合物58(7.90g,23.4mmol)和二氯甲烷(50.0mL),缓慢滴加SO2Cl2(7.15g,46.7mmol),室温下搅拌4.0h。反应液加入50.0mL水稀释,200mL二氯甲烷萃取2次,饱和NaHCO3溶液洗剂,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物59(8.50g,89%)。LCMS:407(M+H)+,RT=1.798min.
在干燥的250mL圆底烧瓶中加入化合物59(0.972g,3mmol),NIS(1.6g,7mmol),和DCM(10.0mL)。室温下搅拌2.0h。反应完毕后,加入200mL水,混合物用200mL二氯甲烷萃取2次,有机相用饱和硫代硫酸钠溶液洗涤,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物60(1.1g,82%)。LCMS:450(M+H)+,RT=1.644min.
在干燥的250mL圆底烧瓶中加入60(9.30g,20.76mmol),p-TSA(0.71g,4.152mmol)和二氯甲烷(50.0mL),缓慢滴加DHP(3.48g,41.52mmol),室温下搅拌4.0h。反应液用50.0mL水稀释,200mL二氯甲烷萃取2次,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物61(7.70g,70%)。LCMS:281(M+H)+,RT=2.165min.
把化合物61(2.0g,3.75mmol)溶解于20mL无水DMF中,然后室温下向溶液中依次加入反式-N,N’-二甲基-1,2-环己二胺(107mg,0.75mmol)、CuI(36mg,0.19mmol)、K3PO4(1.6g,7.5mmol)和A12(1.05g,4.5mmol)。氮气置换3次,升温至110摄氏度,搅拌16个小时。反应完毕后,旋蒸掉溶剂得粗产品,柱层析(二氯甲烷:甲醇=40:1)得62白色固体0.98g,产率为41%。
把化合物62(0.86g,1.35mmol)溶解于10mL二氯甲烷中,然后室温下向溶液中加入三氟乙酸(5ml)。室温下搅拌4个小时。反应完毕后,旋蒸掉溶剂得粗产品,柱层析(二氯甲烷:甲醇=20:1)得白色固体63(0.61g,产率为82%)。
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4-(4-甲基哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm13.37(s,1H),10.81(s,1H),8.39(d,1H,J=8.4Hz),8.01(d,2H,J=8.8Hz),7.08-7.02(m,4H),3.98(s,6H),3.32(m,4H),2.45(m,4H),2.23(s,3H).
使用类似方法可得到如下化合物:
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑[3,4-b]吡啶-3-基)-4-((3S,5R)-3,5-二甲基哌嗪-1-基)苯甲酰胺
1HNMR(CDCl3,400MHz)δppm10.76(brs,1H),8.97(s,1H),8.87(d,1H,J=8.4Hz),7.90(d,2H,J=8.8Hz),7.16(d,1H,J=8.4Hz),6.95(d,2H,J=8.8Hz),6.66(s,1H),3.97(s,6H),3.70(d,2H,J=12.0Hz),3.02(m,2H),2.46(t,2H,J=11.2Hz),1.16(d,6H,J=6.4Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吲唑[3,4-b]吡啶-3-基)-4-(4-乙基哌嗪-1-基)苯甲酰胺
1HNMR(CDCl3,400MHz)δppm10.13(s,1H),8.86(d,1H,J=8.4Hz),8.66(s,1H),7.90(d,2H,J=8.8Hz),7.16(d,1H,J=8.4Hz),6.95(d,2H,J=8.8Hz),6.67(s,1H),3.97(s,6H),3.41-3.79(m,4H),2.64-2.60(m,4H),2.49(q,2H,J=7.2Hz),1.15(t,3H,J=7.2Hz).
N-(6-(2,6-二氯-3,5-二甲氧苯基)-1H-吡唑[3,4-b]并吡啶-3-基)-4-((3R,5S)-3,5-二甲哌嗪-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm13.36(s,1H),10.77(s,1H),8.34(d,1H,J=8.4Hz),7.98(d,2H,J=8Hz),7.30(d,1H,J=8Hz),7.00(d,2H,J=8.8Hz),6.82(d,1H,J=2.8Hz),6.73(d,1H,J=2.8Hz),3.91(s,3H),3.84(s,3H),3.75(d,2H,J=10.4Hz),2.81(s,2H),2.26(s,1H),2.22(d,2H,J=11.2Hz),1.04(s,3H),1.03(s,3H)。LCMS:521(M+H)+,RT=1.233min
N-(6-(2,6-二氯-3,5-二甲氧苯基)-1H-吡唑[3,4-b]并吡啶-3-基)-4-(4-(二甲基氨基)哌啶-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm10.81(s,1H),8.381(d,1H,J=8.4Hz),8.00(d,2H,J=8.8Hz),7.01-7.07(m,4H),3.99(s,6H),3.49-3.51(m,3H),3.26(s,4H),3.17(s,3H),2.55-258(m,5H)。LCMS:585(M+H)+,RT=1.225min.
N-(6-(3,5-二甲氧苯基)-1H-吡唑[3,4-b]并吡啶-3-基)-4-(((3R,5S)-3,5-二甲哌嗪-1-基))苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm13.34(s,1H),10.77(s,1H)8.36(d,1H,J=8.8Hz),7.98(d,2H,J=8.8Hz),7.74(s,1H),7.31(d,2H,J=1.6Hz),7.00(d,2H,J=8.8Hz),6.62(s,1H),3.84(s,6H),3.75(d,2H,J=11.2Hz),2.81(s,2H),2.26(s.1H),2.22(d,2H,J=10.8Hz),1.04(d,6H,J=6Hz).LCMS:487(M+H)+,RT=1.113min.
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑[3,4-b]吡啶-3-基)吡啶甲酰胺
1HNMR(d6-DMSO,400MHz)δppm8.74(s,2H),8.41(d,1H,J=8.0Hz),8.02(d,2H,J=5.6Hz),7.04(s,2H),3.98(s,6H).LCMS:445(M+H)+,RT=1.409min.
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4-吗啉苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm13.42(s,1H),10.86(s,1H),8.41(d,1H,J=7.2Hz),8.05(s,3H),7.07(s,4H),4.00(s,6H),3.77(s,4H),3.30(s,4H).LCMS:528(M+H)+,RT=1.643min.
1HNMR(d6-DMSO,400MHz)δppm13.47(brs,1H),11.03(s,1H),9.28(s,1H),8.89(s,1H),8.71(s,1H),8.41(d,J=8.0Hz,1H),8.28-8.30(m,1H),7.05-7.12(m,3H),4.66(d,J=9.2Hz,2H),3.98(s,6H),3.46(brs,2H),2.83-2.92(m,2H),1.30(d,J=6.4Hz,6H).
1HNMR(d-MeOD,400MHz)δppm8.52(d,J=8.0Hz,1H),8.03(d,J=8.0Hz,2H),7.15-7.13(m,3H),6.94(s,1H),3.99(s,6H),3.58-3.57(m,2H),3.44-3.40(m,4H),1.50(s,6H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4-(2,6-二氮杂螺[3.3]庚烷-2-基)苯甲酰胺
1HNMR(d-MeOD,400MHz)δppm8.49(d,1H,J=8.4Hz),7.94(d,2H,J=8.8Hz),7.12(d,1H,J=8.4Hz),6.94(S,1H),6.55(d,2H,J=8.4Hz),4.08(S,4H),3.98(S,6H),3.83(S,4H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-6-(4-甲基哌嗪-1-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm8.84(s,1H),8.37(d,1H,J=8.4Hz),8.20(d,1H,J=7.6Hz),7.03(s,2H),6.92(d,1H,J=8.8Hz),3.98(s,6H),3.63(s,4H),2.41(t,4H,J=4.0Hz),2.22(s,3H).LCMS:542.2[M+H]+,RT=1.18min。
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-6-(4-乙基哌嗪-1-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm13.40(s,1H),10.91(s,1H),8.84(d,1H,J=2.4Hz),8.41(d,1H,J=8.4Hz),8.19(dd,1H,J1=J2=2.4Hz),7.09(t,2H,J=12.4Hz),6.93(d,1H,J=9.2Hz),3.98(s,6H),3.65(t,4H,J=3.6Hz),2.45(t,4H,J=4.8Hz),2.39(q,2H,J=7.2Hz),1.05(t,3H,J=6.8Hz).LCMS:556.2[M+H]+,RT=1.19min。
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-6-(3,3-二甲基哌嗪-1-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm13.39(s,1H),10.86(s,1H),8.81(d,1H,J=2.0Hz),8.40(d,1H,J=8.0Hz),8.16(dd,1H,J1=2.4Hz,J2=2.4Hz),7.08(t,2H,J=8.4Hz),6.90(d,1H,J=9.2Hz),3.99(s,6H),3.60(t,2H,J=4.0Hz),3.43(s,2H),2.82(t,2H,J=4.4Hz),1.04(s,6H).LCMS:556.2[M+H]+,RT=1.21min。
6-(4-环丙基哌嗪-1-基)-N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm13.40(s,1H),10.92(s,1H),8.85(d,1H,J=1.6Hz),8.41(d,1H,J=8.4Hz),8.20(dd,1H,J1=2.0Hz,J2=1.6Hz),7.08(t,2H,J=8.0Hz),6.94(d,1H,J=9.2Hz),3.98(s,6H),3.62(s,4H),2.62(s,4H),1.66(d,1H,J=3.6Hz),0.46(d,2H,J=4.4Hz),0.38(d,2H,J=2.4Hz).LCMS:568.2[M+H]+,RT=1.21min。
N-(6-(2,6-二氯-3,5-二甲氧苯基)-1H-吡唑[3,4-b]并吡啶-3-基)-4-(4-环丙基哌啶-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm8.34(d,1H,J=8Hz),8.00(d,2H,J=8.8Hz),7.02(t,4H,J=7.8Hz),3.98(s,6H),3.26(s,4H),2.67(s,4H),1.66(s,1H),0.45(d,2H,J=4.8Hz),0.363(s,2H)。LCMS:567(M+H)+,RT=1.22min.
合成路线5
氮气保护下在干燥的250mL三口瓶中加入74(10.00g,43.9mmol)和四氢呋喃(100.0mL),-78℃缓慢滴加异丙基氯化镁氯化锂络合物溶液(2M)(24.2mL,48.3mmol),-78℃—-35℃下搅拌半小时,然后在-78℃下缓慢滴加DMF(9.6g,131.6mmol),在-35℃下搅拌4个小时。反应用饱和氯化铵溶液在-78℃下淬灭,反应液用100.0mL水稀释,200mL乙酸乙酯萃取2次,合并有机相,无水硫酸钠干燥,旋干溶剂得化合物75(2.1g,31%)为白色固体。
1HNMR(DMSO-d6,400MHz)δppm10.19(s,1H),9.12(s,1H).
化合物75(2.0g,11.3mmol)溶入THF(10mL)中,在0℃加入水合肼(1.33g,22.6mmol)的THF(20mL)溶液,反应液在室温下搅拌半小时过硅胶柱纯化得到化合物76为黄色固体(1.0g,57%)。LCMS:155(M+H)+,RT=0.929min.
把化合物76(1.0g,6.5mmol),DHP(1.1g,13mmol)和PTSA(224mg,1.3mmol)溶入30ml二氯甲烷中室温过夜,混合物拌硅胶过柱纯化得到黄色固体化合物77(1.0g,65%)。LCMS:239(M+H)+,RT=1.32min。
化合物77(900mg,3.8mmol),3,5-二甲氧基苯硼酸(826mg,4.5mmol),Pd(dppf)Cl2(415mg,0.57mmol)和磷酸钾(960mg,4.5mmol)溶入1,4-二氧六环(12mL)中110℃微波反应90分钟,过硅胶柱纯化得到黄色固体化合物78(950mg,74%)。LCMS:341(M+H)+,RT=1.803min。
化合物78(500mg,1.5mmol)溶入10mL二氯甲烷中,0℃下加入磺酰氯(446mg,3.3mmol),室温搅拌4小时,LCMS检测无原料剩余,反应液加少量水淬灭过硅胶柱纯化得到白色固体化合物79(460mg,84%)。LCMS:325(M+H)+,RT=1.24min.
化合物79(400mg,1.23mmol)和NIS(554mg,2.46mmol)溶入5mLDMF中80℃过夜。反应液油泵旋干过硅胶柱纯化得化合物80(370mg,67%)。LCMS:450(M+H)+,RT=1.577min.
将化合物80(370mg,0.82mmol),DHP(138mg,1.64mmol)和PTSA(28mg,0.16mmol)溶入10mL二氯甲烷中室温搅拌4小时,混合物过柱纯化得黄色固体化合物81(450mg,100%)。LCMS:534(M+H)+,RT=1.964min。
把化合物81(100mg,0.19mmol),4-(4-甲基哌嗪-1-基)苯甲酰胺(82mg,0.37mmol),CuI(7mg,0.037mmol),K3PO4(119mg,0.56mmol)和N,N’-二甲基-1,2-环己二胺(5mg,0.037mmol)溶解于3mLDMF中,110℃搅拌过夜,旋干过柱纯化,得到褐色油状化合物82为55mg,产率为47%。LCMS:626(M+H)+,RT=1.37min。
把化合物82(55mg,0.088mmol)和2mL三氟乙酸溶于2mL二氯甲烷中,室温过夜,反应完毕后,旋蒸掉溶剂得粗产品,pre-TLC纯化后pre-HPLC纯化得4mg黄色固体产物83,产率为8%。LCMS:542(M+H)+,RT=1.27min。
1HNMR(d-MeOD,400MHz)δppm9.76(s,1H),8.06(d,2H,J=8.8Hz),7.16(d,2H,J=8.8Hz),6.96(s,1H),4.13(d,2H,J=10Hz),3.99(s,6H),3.63(d,2H,J=2.8Hz),3.21-3.17(m,4H),2.99(s,3H)。
使用类似方法可得到如下化合物:
N-(6-(2,6-二氯-3,5-二甲氧苯基)-1H-吡唑[3,4-d]并嘧啶-3-基)-4-((3R,5S)-3,5-二甲哌嗪-1-基)苯甲酰胺
1HNMR(d-MeOD,400MHz)δppm9.76(s,1H),8.05(d,2H,J=8.8Hz),7.17(d,2H,J=8.8Hz),6.96(s,1H),3.99(s,6H),3.53-3.49(m,2H),3.42-3.38(m,2H),2.86-2.80(m,2H),1.48(d,6H,J=5.2Hz)。LCMS:556(M+H)+,RT=1.33min。
使用合成化合物63的方法可得到以下化合物:
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-6-(4-甲基哌嗪-1-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm8.84(s,1H),8.37(d,1H,J=8.4Hz),8.20(d,1H,J=7.6Hz),7.03(s,2H),6.92(d,1H,J=8.8Hz),3.98(s,6H),3.63(s,4H),2.41(t,4H,J=4.0Hz),2.22(s,3H).LCMS:542.2[M+H]+,RT=1.18min。
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-6-(4-乙基哌嗪-1-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm13.40(s,1H),10.91(s,1H),8.84(d,1H,J=2.4Hz),8.41(d,1H,J=8.4Hz),8.19(dd,1H,J1=J2=2.4Hz),7.09(t,2H,J=12.4Hz),6.93(d,1H,J=9.2Hz),3.98(s,6H),3.65(t,4H,J=3.6Hz),2.45(t,4H,J=4.8Hz),2.39(q,2H,J=7.2Hz),1.05(t,3H,J=6.8Hz).LCMS:556.2[M+H]+,RT=1.19min。
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-6-(3,3-二甲基哌嗪-1-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm13.39(s,1H),10.86(s,1H),8.81(d,1H,J=2.0Hz),8.40(d,1H,J=8.0Hz),8.16(dd,1H,J1=2.4Hz,J2=2.4Hz),7.08(t,2H,J=8.4Hz),6.90(d,1H,J=9.2Hz),3.99(s,6H),3.60(t,2H,J=4.0Hz),3.43(s,2H),2.82(t,2H,J=4.4Hz),1.04(s,6H).LCMS:556.2[M+H]+,RT=1.21min。
6-(4-环丙基哌嗪-1-基)-N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)烟酰胺
1HNMR(DMSO-d6,400MHz)δppm13.40(s,1H),10.92(s,1H),8.85(d,1H,J=1.6Hz),8.41(d,1H,J=8.4Hz),8.20(dd,1H,J1=2.0Hz,J2=1.6Hz),7.08(t,2H,J=8.0Hz),6.94(d,1H,J=9.2Hz),3.98(s,6H),3.62(s,4H),2.62(s,4H),1.66(d,1H,J=3.6Hz),0.46(d,2H,J=4.4Hz),0.38(d,2H,J=2.4Hz).LCMS:568.2[M+H]+,RT=1.21min。
N-(6-(2,6-二氯-3,5-二甲氧苯基)-1H-吡唑[3,4-b]并吡啶-3-基)-4-(4-环丙基哌啶-1-基)苯甲酰胺
1HNMR(d6-DMSO,400MHz)δppm8.34(d,1H,J=8Hz),8.00(d,2H,J=8.8Hz),7.02(t,4H,J=7.8Hz),3.98(s,6H),3.26(s,4H),2.67(s,4H),1.66(s,1H),0.45(d,2H,J=4.8Hz),0.363(s,2H)。LCMS:567(M+H)+,RT=1.22min.
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4--((3S,5R)-3,4,5-三甲基哌啶-1-基)苯甲酰胺
1HNMR(400MHz,DMSO-d6):13.41(s,1H),10.90(s,1H),9.38(s,1H),8.39(d,1H,J=8.0Hz),8.06(d,2H,J=8.8Hz),7.16(d,2H,J=9.2Hz),7.09(d,1H,J=12.4Hz),7.05(s,1H),4.19(d,2H,J=13.6Hz),3.99(s,6H),3.35-3.44(m,2H),2.90-2.95(m,2H),2.88(d,3H,J=4.4Hz),1.39(d,6H,J=6.4Hz).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4-(3,3-二甲基哌嗪-1-基)-3-氟苯甲酰胺
1HNMR(400MHz,DMSO-d6):13.48(s,1H),11.10(s,1H),8.86(brs,1H),8.39(d,1H,J=8.0Hz),7.96~7.92(m,2H),7.25(t,1H,J=8.8Hz),7.10(d,1H,J=2.8Hz),7.05(s,1H),3.99(s,6H),3.35(s,4H),3.18(s,2H),1.41(s,6H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-2-(4-甲基哌嗪-1-基)嘧啶-5-甲酰胺
1HNMR(400MHz,DMSO-d6):13.46(s,1H),11.08(s,1H),9.00(s,2H),8.42(d,1H,J=8.4Hz),8.33(s,1H),7.09(d,1H,J=8.4Hz),7.05(s,1H),3.99(s,6H),3.85-3.88(m,4H),2.38-2.40(m,4H),2.23(s,3H).
使用类似合成44的方法可得到如下化合物:
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(哌啶-1-基)苯甲酰胺
1HNMR(400MHz,DMSO-d6):12.85(s,1H),10.38(s,1H),7.87(d,2H,J=8.8Hz),7.77(d,1H,J=8.4Hz),7.50(s,1H),7.08(t,2H,J=8.4Hz),6.62(d,2H,J=8.8Hz),6.34(d,1H,J=6.4Hz),3.92(s,6H),3.77-3.82(m,1H),1.91-2.00(m,2H),1.65-1.73(m,2H),1.55-1.62(m,2H),1.45-1.51(m,2H).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-((4-甲基哌嗪-1-基)甲基)苯甲酰胺
1HNMR(400MHz,DMSO-d6):13.01(s,1H),10.91(s,1H),8.10(s,2H),7.79(s,1H),7.54(s,3H),7.08(s,2H),3.91(s,6H),3.83(s,2H),3.36-3.48(m,2H),2.95-3.14(m,4H),2.79(s,3H),2.50-2.58(m,2H).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(4-甲基-1,4-二氮杂环庚烷-1-基)苯甲酰胺
1HNMR(400MHz,DMSO-d6):13.91(s,1H),10.56(s,1H),9.81(s,1H),8.02(d,2H,J=8.4Hz),7.78(d,1H,J=8.4Hz),7.52(s,1H),7.06-7.09(m,2H),6.89(d,2H,J=8.8Hz),3.92(s,6H),3.85-3.96(m,2H),3.67-3.74(m,1H),3.45-3.58(m,3H),3.12-3.26(m,1H),2.86(d,3H,J=3.6Hz),2.15-2.25(m,2H).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-2-(4-甲基哌嗪-1-基)嘧啶-5-甲酰胺
1HNMR(400MHz,DMSO-d6):12.99(s,1H),10.95(s,1H),9.08(s,2H),7.84(d,1H,J=8.4Hz),7.54(s,1H),7.06-7.11(m,2H),4.75-4.95(m,2H),3.92(s,6H),3.35-3.55(m,2H),3.05-3.35(m,4H),2.84(s,3H).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(3,3-二甲基哌嗪-1-基)-3-甲氧基苯甲酰胺
1HNMR(400MHz,MeOD):7.86(d,1H,J=8.4Hz),7.69-7.72(m,2H),7.54(s,1H),7.18(d,1H,J=8.4Hz),7.09(d,1H,J=8.0Hz),6.94(t,1H,J=8.0Hz),3.98(s,3H),3.93(s,6H),3.42-3.45(m,2H),3.35-3.39(m,2H),3.19(s,2H),1.54(s,6H).
N-(6-(2,6-二氟-3,5-二甲氧基苯基)-1H-吲唑-3-基)-4-(3-(二甲氨基)吡咯烷-1-基)苯甲酰胺
1HNMR(400MHz,DMSO-d6):12.88(s,1H),10.51(s,1H),8.00-8.01(m,2H),7.78-7.80(m,1H),7.51(s,1H),7.08(s,2H),6.65-6.67(m,2H),3.92(s,6H),3.62-3.71(m,1H),3.51-3.60(m,1H),2.50(s,6H),2.26-2.35(m,2H),1.97-2.15(m,1H).
使用合成化合物63的方法可得到以下化合物:
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4-(3,3,5,5-四甲基哌啶-1-基)苯甲酰胺
1HNMR(400MHz,MeOD):8.51(d,1H,J=8.4Hz),8.03(d,1H,J=7.6Hz),7.12-7.22(m,3H),6.95(s,1H),3.99(s,6H),3.47(s,4H),1.52(s,12H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)基)-4-(3-(二甲氨基)吡咯烷-1-基)苯甲酰胺
1HNMR(400MHz,MeOD):8.27(d,1H,J=8.4Hz),8.01(d,2H,J=8.4Hz),7.12(d,1H,J=8.4Hz),6.94(s,1H),6.79(d,2H,J=8.4Hz),4.06-4.13(m,1H),3.99(s,6H),3.85-3.93(m,1H),3.70-3.75(m,1H),3.61-3.65(m,1H),3.46-3.52(m,1H),3.01(s,6H),2.60-2.67(m,1H),2.26-2.36(m,1H).
N-(6-(2,6-二氯-3,5-二甲氧基苯基)-1H-吡唑并[3,4-b]吡啶-3-基)-4-(3,3-二甲基哌嗪-1-基)-3-甲氧基苯甲酰胺
1HNMR(400MHz,DMSO-d6):13.46(s,1H),11.07(s,1H),8.41(d,1H,J=8.4Hz),7.23-7.50(m,2H),7.06-7.11(m,3H),3.99(s,6H),3.92(s,3H),3.29(s,2H),3.25(s,2H),3.07(s,2H),2.58(s,1H),1.41(s,6H).